What is amycretin and how does it work?

Amycretin (zenagamtide) is Novo Nordisk's investigational dual-agonist that activates both GLP-1 and amylin receptors simultaneously. GLP-1 reduces appetite and slows gastric emptying, while amylin adds a complementary satiety signal through distinct brain pathways.

How much weight loss does amycretin produce?

In Phase 1b/2 trials, the injectable formulation produced 22% mean body weight loss over 36 weeks — and the curve had not yet plateaued. This is higher than semaglutide's 14.9% at 68 weeks, though direct cross-trial comparisons are limited.

Is amycretin FDA-approved and available?

No. Amycretin is not FDA-approved and is not available for prescription. Phase 3 trials began in Q1 2026. The earliest realistic availability is 2029–2030 for the injectable, and 2030 or later for the oral formulation.

Will there be an oral amycretin pill?

Yes. Novo Nordisk is developing both injectable and oral formulations in parallel. The oral version is further behind in development and could potentially be approved around 2030 or later, pending successful Phase 3 results.

Patient Guides

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

Updated March 28, 2026

Fact Checked

Complete guide to amycretin (zenagamtide) — Novo Nordisk's GLP-1/amylin dual agonist with 22% weight loss in early trials. Phase 3 starting 2026, oral and injectable paths.

Key Takeaways

Injectable amycretin produced 22% mean body weight loss at 36 weeks in Phase 1b/2 trials — curve not yet plateaued.
Amycretin activates both GLP-1 and amylin receptors simultaneously, a mechanism no approved drug currently uses.
Phase 3 trials began Q1 2026; earliest injectable approval is 2029–2030, oral formulation likely 2030 or later.
In REDEFINE comparison context, tirzepatide (Zepbound) produced 20.9% at 72 weeks and is available today.
Nausea affects approximately 30% of patients during titration — consistent with the GLP-1 class profile.

On this page

Find your match

Answer a few questions and we’ll match you with the right provider and medication.

Take the Quiz →

Free · 2 min · No signup required

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

Amycretin (also known as zenagamtide or NNC0487-0111) is Novo Nordisk's investigational dual-agonist medication that activates both GLP-1 and amylin receptors simultaneously. In a Phase 1b/2 trial, the injectable formulation produced 22% mean body weight loss over 36 weeks — a rate of loss that, if sustained, could rival or exceed the most effective medications in the class.

Amycretin is not FDA-approved and is not available for prescription. It entered Phase 3 clinical trials in Q1 2026. The drug has not been submitted to the FDA. Even under an optimistic timeline, the earliest realistic availability is 2028 or later.

What makes amycretin particularly interesting is not just the weight loss numbers — it's that Novo Nordisk is developing both injectable and oral formulations in parallel. An effective oral GLP-1/amylin dual agonist would represent a significant advance in how obesity is treated.

Everything in this guide is based on published clinical trial data and Novo Nordisk disclosures, all of which are subject to change.

Here's what we know so far.

What Is Amycretin?

Amycretin is a single molecule engineered to activate two distinct hormone receptors — unlike any currently approved obesity medication, it targets both GLP-1 and amylin pathways simultaneously. Amycretin is a single molecule engineered to activate two distinct hormone receptors: GLP-1 and amylin. This dual-agonist approach combines the well-established appetite-reducing effects of GLP-1 with amylin's separate and complementary satiety signals — a mechanism no currently approved medication exploits.

Key facts:

Type: Dual-agonist (GLP-1 and amylin receptor agonist)
Manufacturer: Novo Nordisk
Routes in development: Both subcutaneous injection (weekly) and oral tablet (daily)
FDA status: Not approved — Phase 3 clinical trials initiated Q1 2026
Phase 1b/2 results: 22% mean weight loss (injectable, 36 weeks); oral formulation also in clinical testing
Studied for: Obesity and overweight
Other names: Zenagamtide, NNC0487-0111

How Does the GLP-1/Amylin Mechanism Work?

Amycretin's dual mechanism is what separates it from all other GLP-1 drugs: it activates the amylin receptor simultaneously with GLP-1, recruiting a second independent satiety pathway in the brain. Every approved GLP-1 medication works primarily through one or two receptors — GLP-1 alone (semaglutide) or GLP-1 plus GIP (tirzepatide). Amycretin takes a different path by pairing GLP-1 with amylin. Here's what each receptor does and why the combination matters.

GLP-1 receptor: the established foundation

This is the receptor that semaglutide (Wegovy/Ozempic) and all other GLP-1 drugs activate. It reduces appetite, slows gastric emptying, improves blood sugar control, and has demonstrated cardiovascular benefits in dedicated outcomes trials. GLP-1 receptor agonism is the most validated approach in modern obesity pharmacotherapy.

Amylin receptor: a different satiety pathway

Amylin is a hormone co-secreted with insulin from the pancreatic beta cells after meals. It works through brain regions that are distinct from — but complementary to — the areas targeted by GLP-1:

Area postrema and nucleus tractus solitarius. Amylin acts on these brainstem areas to promote satiety and reduce meal size. GLP-1 also signals through these regions, but amylin activates different neuronal populations within them, producing additive effects.
Slows gastric emptying through a separate mechanism. Like GLP-1, amylin slows the rate at which food leaves the stomach. But it does so through distinct neural pathways, meaning the combination may produce a more sustained reduction in post-meal hunger than either signal alone.
Reduces glucagon secretion. Amylin suppresses post-meal glucagon release, which helps with blood sugar regulation — particularly relevant for patients with type 2 diabetes.
May reduce food reward signaling. Preclinical research suggests amylin modulates reward-related feeding behavior, which could help reduce cravings and hedonic eating — the eating driven by pleasure rather than hunger.

Why the combination matters

The core insight behind amycretin is that appetite is not controlled by a single signal. GLP-1 and amylin reduce hunger through overlapping but distinct brain circuits. By activating both simultaneously with a single molecule, amycretin aims to produce a more complete suppression of appetite than either pathway can achieve alone.

This is a fundamentally different strategy from tirzepatide (GLP-1/GIP) or retatrutide (GLP-1/GIP/glucagon). Those drugs amplify or broaden the metabolic response. Amycretin doubles down on satiety — the subjective experience of feeling full and not wanting to eat — through two independent neural channels.

Whether this translates into better long-term outcomes than the GIP or glucagon-based approaches is an open question. The Phase 1b/2 data is encouraging, but only larger and longer trials will tell us how the amylin component holds up.

How Effective Is Amycretin?

In Phase 1b/2 trials, amycretin's injectable formulation produced 22% mean weight loss at 36 weeks — still trending downward at the last measurement point. Amycretin is earlier in its clinical development than medications like retatrutide or survodutide. The data we have comes primarily from Phase 1b/2 trials, which involve smaller patient populations and shorter durations than Phase 3. The results are promising but preliminary.

Phase 1b/2 Trial: Injectable Formulation

Novo Nordisk's Phase 1b/2 trial for injectable amycretin enrolled participants with obesity (BMI 30 or above, or BMI 27 or above with weight-related comorbidity) and ran for 36 weeks:

22% mean body weight loss at the highest tested dose over 36 weeks
Weight loss trajectory had not yet plateaued at 36 weeks — the curve was still descending
The rate of weight loss was notably fast compared to other GLP-1-class agents at similar timepoints

To put the speed in context: semaglutide 2.4 mg (Wegovy) produces roughly 10-12% weight loss at 36 weeks, reaching its plateau of approximately 15% around week 60-68. Amycretin was already at 22% at 36 weeks with no plateau in sight. If the trajectory continues — a significant "if" — the eventual total weight loss could be substantially higher.

Phase 1b/2 Trial: Oral Formulation

Novo Nordisk has also disclosed early data on an oral formulation of amycretin:

Clinically meaningful weight loss was observed in the oral cohort, though the magnitude was lower than the injectable formulation at equivalent timepoints
The oral formulation demonstrated proof of concept — showing that a GLP-1/amylin dual agonist can be delivered effectively as a pill
Detailed results from the oral program are expected as trials progress through Phase 2 and into Phase 3

The oral data is earlier-stage and less mature. Novo Nordisk has been cautious about releasing specific numbers, which is typical for oral programs where dose optimization is still underway.

What the early data tells us — and what it doesn't

What it tells us: The GLP-1/amylin combination produces rapid, substantial weight loss that appears to exceed semaglutide alone at comparable timepoints. The amylin component is adding clinically meaningful benefit beyond what GLP-1 agonism achieves on its own.

What it doesn't tell us: Phase 1b/2 trials are small (typically dozens to low hundreds of participants), short relative to chronic obesity treatment, and involve carefully selected patient populations. We do not yet know:

What the maximum weight loss will be once the curve plateaus
Whether the results will hold in a larger, more diverse Phase 3 population
How the side effect profile looks in thousands rather than hundreds of patients
Whether the weight loss translates into cardiovascular or other hard clinical outcomes
How the oral formulation compares to the injectable at optimized doses

Phase 3 will answer these questions. Until then, the 22% number is a strong signal, not a confirmed result.

Oral vs. Injectable: Two Paths Forward

One of the most strategically significant aspects of amycretin's development is that Novo Nordisk is pursuing both oral and injectable formulations. This is not just a matter of patient convenience — it reflects a broader shift in how GLP-1-class medications may be delivered.

The injectable path

Once-weekly subcutaneous injection (similar to semaglutide and tirzepatide)
22% weight loss at 36 weeks in Phase 1b/2 — the strongest early data
Phase 3 initiated Q1 2026
This is the more advanced program and likely to reach FDA submission first
If approved, would compete directly with Wegovy, Zepbound, and any approved retatrutide

The oral path

Daily oral tablet (specific dosing regimen not yet finalized)
Earlier in development than the injectable, but actively progressing
Addresses the substantial patient population that strongly prefers pills over injections
If successful, would compete with Novo's own oral Wegovy (oral semaglutide 25 mg, approved 2025) as well as Eli Lilly's orforglipron
Could eventually become the preferred oral obesity medication if weight loss exceeds oral semaglutide

Why both matter

The oral formulation is arguably the bigger long-term opportunity. Despite the effectiveness of injectable GLP-1s, a significant portion of patients either refuse injections, have needle anxiety, or would prefer the simplicity of a daily pill. Oral semaglutide (Rybelsus for T2D, oral Wegovy for obesity) proved the concept, but its weight loss of approximately 16.6% at the 25 mg dose leaves room for improvement.

An oral amycretin that delivers 18-22% weight loss via pill could be transformative for the obesity treatment landscape. That said, oral peptide delivery is technically challenging — bioavailability, food interactions, and dose optimization all create hurdles that do not exist with injections. The oral program's success is not guaranteed by the injectable program's results.

How Does Amycretin Compare to Existing and Pipeline GLP-1s?

Amycretin's 22% Phase 1b/2 weight loss puts it above semaglutide and comparable to tirzepatide in early data — but it is not yet FDA-approved, and direct cross-trial comparisons are unreliable. The obligatory comparison table, with the standard caveat: these numbers come from different trials, different patient populations, different durations, and different protocols. Cross-trial comparison is informative but inherently imprecise. Only head-to-head trials can truly compare medications.

Medication	Mechanism	Route	Mean Weight Loss	Trial Duration	FDA Status
Amycretin (injectable)	GLP-1 + Amylin	Weekly injection	22%	36 weeks (not plateaued)	Not approved — Phase 3
Retatrutide (12 mg)	GLP-1 + GIP + Glucagon	Weekly injection	28.7%	48 weeks (not plateaued)	Not approved — Phase 3
Zepbound/tirzepatide (15 mg)	GLP-1 + GIP	Weekly injection	20.9%	72 weeks	Approved (2023)
Oral Wegovy (25 mg)	GLP-1 only	Daily pill	16.6%	64 weeks	Approved (2025)
Wegovy/semaglutide (2.4 mg)	GLP-1 only	Weekly injection	14.9%	68 weeks	Approved (2021)
Orforglipron (36 mg)	GLP-1 only	Daily pill	11.2%	72 weeks	Approved (2025)

Amycretin vs. Semaglutide (Wegovy)

Factor	Amycretin (injectable)	Semaglutide (Wegovy)
Receptors	GLP-1 + Amylin	GLP-1 only
Weight loss	22% at 36 weeks (Phase 1b/2)	14.9% at 68 weeks (Phase 3)
Route	Weekly injection	Weekly injection or daily pill
FDA status	Not approved	Approved (2021)
Cardiovascular outcomes data	None	SELECT trial: 20% CV risk reduction
Real-world data	None (trial only)	Most extensive in class
Manufacturer	Novo Nordisk	Novo Nordisk

The honest take: Amycretin and semaglutide come from the same company. Semaglutide has the most clinical evidence of any GLP-1 medication — including the SELECT cardiovascular outcomes trial showing a 20% reduction in major cardiac events. Amycretin produces substantially more weight loss in early trials, but we have no cardiovascular outcomes data, no long-term safety data, and no real-world experience. Semaglutide is the known quantity. Amycretin is the promising successor, but "promising" and "proven" are different things.

Amycretin vs. Tirzepatide (Zepbound)

Factor	Amycretin (injectable)	Tirzepatide (Zepbound)
Receptors	GLP-1 + Amylin	GLP-1 + GIP
Weight loss	22% at 36 weeks (Phase 1b/2)	20.9% at 72 weeks (Phase 3)
Route	Weekly injection	Weekly injection
FDA status	Not approved	Approved (2023)
Availability	Not available	Available now
Manufacturer	Novo Nordisk	Eli Lilly

The honest take: These are the two leading approaches to improving on semaglutide — but they use completely different second receptors. Tirzepatide adds GIP (a metabolic amplifier), while amycretin adds amylin (a satiety enhancer). Amycretin's 22% at 36 weeks is impressive given the shorter trial duration, but Phase 1b/2 numbers frequently shift in Phase 3. Tirzepatide is available now with extensive real-world data. The comparison will become more meaningful once amycretin Phase 3 results are available.

Amycretin vs. Retatrutide

Factor	Amycretin (injectable)	Retatrutide
Receptors	GLP-1 + Amylin	GLP-1 + GIP + Glucagon
Weight loss	22% at 36 weeks (Phase 1b/2)	28.7% at 48 weeks (Phase 3)
Liver fat reduction	Unknown	~80-90%
Route	Weekly injection	Weekly injection
Oral formulation	Yes (in development)	No
FDA status	Not approved — Phase 3	Not approved — Phase 3
Manufacturer	Novo Nordisk	Eli Lilly

The honest take: Retatrutide's Phase 3 weight loss (28.7%) is substantially higher than amycretin's Phase 1b/2 result (22%), though direct comparison is unfair given the different trial phases and durations. Retatrutide also has unique benefits for liver fat via the glucagon receptor. Amycretin's key differentiator is the oral formulation — retatrutide has no oral path. If you're comparing these two as injectable-only, retatrutide currently has the edge on raw weight loss. If the oral amycretin delivers strong results, it occupies a space retatrutide cannot.

Novo Nordisk's Strategy

Amycretin sits within a broader Novo Nordisk pipeline strategy that is worth understanding. Novo is not developing amycretin in isolation — it's building a portfolio designed to maintain dominance as the GLP-1 market evolves.

The competitive context

Novo Nordisk created the GLP-1 obesity market with semaglutide (Wegovy), but Eli Lilly has been gaining ground rapidly:

Tirzepatide (Zepbound) produces more weight loss than semaglutide and is taking market share
Retatrutide could produce even more weight loss and is progressing through Phase 3
Orforglipron gives Lilly an oral option at a lower price point

Novo needs next-generation molecules to maintain its position. Amycretin — particularly the oral formulation — is a central part of that response.

Novo's pipeline positioning

Molecule	Stage	Role
Semaglutide (Wegovy/Ozempic)	Marketed	Current flagship — injectable and oral
Oral semaglutide 25 mg (oral Wegovy)	Approved 2025	Oral obesity option — bridges to next-gen
CagriSema	Phase 3	Cagrilintide (amylin analog) + semaglutide co-formulation
Amycretin (injectable)	Phase 3	Single-molecule GLP-1/amylin — next-gen injectable
Amycretin (oral)	Phase 2/3	Single-molecule GLP-1/amylin — next-gen oral

The CagriSema connection

To understand amycretin, you also need to know about CagriSema — Novo's other GLP-1/amylin combination. CagriSema is a co-formulation of cagrilintide (a long-acting amylin analog) and semaglutide, delivered as a single weekly injection but containing two separate molecules.

Amycretin is the single-molecule version of the same concept. Instead of combining two drugs in one syringe, Novo engineered one molecule that activates both receptors. This matters because:

A single molecule is simpler to manufacture and dose
A single molecule can potentially be formulated as a pill (two large peptides in one pill is much harder)
It may offer more predictable pharmacokinetics (one molecule, one absorption curve, one half-life)

CagriSema is further along in development (Phase 3 results reported), but amycretin may ultimately be the more versatile and commercially important molecule — especially if the oral formulation succeeds.

What this means for patients

Novo Nordisk is investing heavily in the GLP-1/amylin combination approach. If either CagriSema or amycretin delivers in Phase 3, patients will eventually have access to medications that target satiety through two independent brain pathways. And if oral amycretin works, patients who prefer pills over injections will have an option that could meaningfully surpass oral semaglutide in effectiveness.

The risk: Novo is betting big on amylin, and if amylin agonism turns out to add less benefit than GIP (tirzepatide's approach) or glucagon (retatrutide's approach), Lilly's pipeline may prove more effective. The Phase 3 data will be decisive.

When Will Amycretin Be Available?

Amycretin's injectable form is the earliest-stage next-gen GLP-1 entering Phase 3 — but 2029–2030 approval is the optimistic scenario, and it is not worth waiting for if effective medications are available now. Here's the realistic timeline based on where amycretin stands in development:

Milestone	Expected Timing
Phase 3 trials initiated	Q1 2026 (confirmed)
Phase 3 interim or topline results	Late 2027 - 2028
Full Phase 3 results published	2028
NDA/BLA submission to FDA (if Phase 3 successful)	2028 - 2029
FDA review period	10-12 months (standard) or 6-8 months (priority)
Potential FDA approval (injectable)	2029 - 2030
Oral formulation approval (likely later)	2030+
Broad pharmacy availability	Weeks to months after approval

Important timeline caveats:

The injectable formulation is ahead of the oral. If both succeed, expect the injectable to reach market first.
Phase 3 trials can take 2-3 years to fully enroll, treat, and report. Novo Nordisk has not disclosed specific Phase 3 completion dates for amycretin.
Regulatory timelines depend on how clean the data is. Priority review is possible if amycretin demonstrates a clear advance over approved options, but not guaranteed.
Manufacturing scale-up for a new molecule takes time. Even after approval, supply constraints are possible — the GLP-1 class has a history of shortages.

On pricing: Novo Nordisk has not disclosed expected pricing. For context, Wegovy is currently $499-$799/month self-pay depending on dose, and oral Wegovy launched at $399/month. Amycretin, as a next-generation molecule, could be priced at a premium to semaglutide — or Novo could price aggressively to compete with Lilly's growing portfolio. It is too early to speculate meaningfully.

On compounding: There is no legal pathway for compounded amycretin. It is a patented investigational drug that has never been commercially manufactured. Any "amycretin" or "zenagamtide" sold online is an unregulated, unverified product. We strongly advise against purchasing it.

What Are the Most Common Side Effects of Amycretin?

Amycretin's Phase 1b/2 data shows a GI side effect profile broadly similar to semaglutide, with nausea around 30% during titration — the amylin component does not appear to dramatically worsen tolerability. Based on Phase 1b/2 data, amycretin's side effect profile is broadly consistent with the GLP-1 class, with some nuances introduced by the amylin component.

Gastrointestinal (most common)

The most frequently reported side effects were gastrointestinal, which is expected for any medication that activates GLP-1 receptors:

Nausea — the most common side effect, occurring at rates similar to or modestly higher than semaglutide at equivalent timepoints
Vomiting — reported in a minority of participants, generally during dose escalation
Diarrhea — frequency comparable to other GLP-1 medications
Decreased appetite — an expected therapeutic effect, not truly a side effect

These were generally mild to moderate in severity, most pronounced during the dose-escalation period, and tended to diminish with continued treatment. This pattern is consistent with semaglutide and tirzepatide.

The amylin factor

The amylin receptor activation introduces some considerations specific to this class:

Nausea may be modestly higher. Amylin acts on the area postrema — a brain region involved in nausea. Native amylin analogs (like pramlintide, marketed as Symlin for diabetes) are known to cause nausea, particularly early in treatment. In amycretin, the amylin component may contribute to somewhat higher nausea rates than a GLP-1-only drug, though this has not been precisely quantified in the early data.
No unexpected safety signals. Phase 1b/2 data did not reveal any new or unexpected adverse effects beyond what is seen with GLP-1 agonists. This is reassuring but not conclusive — rare side effects may only emerge in larger Phase 3 populations.

What we don't know yet

Phase 1b/2 trials involve hundreds of participants at most. Phase 3 trials enroll thousands. Many clinically important side effects — particularly rare events like pancreatitis, thyroid concerns, or gallbladder issues that have been associated with other GLP-1 medications — can only be adequately assessed in larger populations with longer follow-up.

There is also no cardiovascular outcomes data for amycretin. Semaglutide's SELECT trial and tirzepatide's ongoing outcomes studies will set the bar that amycretin will eventually need to meet. Until that data exists, we cannot assume that amycretin's weight loss translates into cardiovascular benefit — even though it is a reasonable expectation based on what we know about the GLP-1 class.

Frequently Asked Questions

Can I get amycretin now?

No. Amycretin is not FDA-approved and is not available through any pharmacy, telehealth platform, or legitimate prescriber. The only way to access it is through enrollment in a clinical trial. Phase 3 trials are now recruiting — search ClinicalTrials.gov for "amycretin" or "zenagamtide" or "NNC0487-0111" to find active sites. Eligibility criteria are strict, and you should discuss with your physician whether participation is appropriate.

Anyone claiming to sell amycretin outside of a clinical trial is selling an unregulated product with unknown safety and composition.

Is amycretin better than semaglutide?

It produces more weight loss in early trials (22% at 36 weeks vs. semaglutide's 14.9% at 68 weeks). But "better" is context-dependent. Semaglutide has the SELECT cardiovascular outcomes trial proving a 20% reduction in major cardiac events, years of real-world safety data, and is available today. Amycretin has a Phase 1b/2 result. Promising data and proven medicine are not the same thing. If you're making a treatment decision today, semaglutide and tirzepatide are the options that exist.

How does amycretin compare to tirzepatide?

Different approaches to the same problem. Tirzepatide adds GIP to GLP-1, producing 20.9% weight loss. Amycretin adds amylin to GLP-1, producing 22% at a shorter timepoint but in an earlier-stage trial. The comparison will become clearer when amycretin Phase 3 data is available. Currently, tirzepatide is approved, available, and extensively studied. Amycretin is not.

Will amycretin replace Wegovy?

Not immediately, and probably not entirely. Novo Nordisk makes both. The most likely scenario is that semaglutide (Wegovy) remains available for patients who respond well to it, while amycretin — if approved — is positioned as a more potent next-generation option, potentially at a higher price point. Novo may also prioritize the oral amycretin formulation as a replacement for oral semaglutide if it proves more effective. The exact commercial strategy will depend on Phase 3 results.

What about the oral formulation — when will that be available?

The oral formulation is behind the injectable in development. A realistic timeline would be 2030 or later for potential approval. Oral peptide formulations face additional challenges in manufacturing, bioavailability, and dose optimization. If the injectable amycretin is approved around 2029, the oral version could follow one to two years later — but this is speculative.

How is amycretin different from CagriSema?

Both combine GLP-1 and amylin receptor activation, but in different ways. CagriSema is a co-formulation of two separate molecules (cagrilintide + semaglutide) in one injection. Amycretin is a single molecule engineered to hit both receptors. The single-molecule approach is what enables the oral formulation — getting two large peptides absorbed from a pill is much harder than getting one. Amycretin may ultimately be the more versatile platform, while CagriSema may reach market first.

Should I wait for amycretin instead of starting a GLP-1 now?

For most people, no. Amycretin is at minimum 3-4 years from potential availability. That is a long time to delay treatment for obesity, which carries its own health risks. Patients searching "what GLP-1 do doctors prescribe most" will find semaglutide and tirzepatide — both available today. Effective medications are available or expected imminently — including semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (awaiting FDA approval, PDUFA April 10, 2026). Starting treatment now does not prevent you from switching to amycretin later if it becomes available and your prescriber recommends it. Delaying treatment for a drug that hasn't been approved means forgoing real health benefits today for a hypothetical future option.

Is the 22% weight loss number reliable?

The number comes from a Novo Nordisk Phase 1b/2 trial, which is conducted under regulatory standards and published protocols. It is a real result from a real trial. However, Phase 1b/2 trials are smaller and shorter than Phase 3, and results sometimes shift — in either direction — when tested in larger populations. The 22% is a strong signal of efficacy, not a final answer. Phase 3 will provide the definitive data.

What about compounded amycretin?

It does not exist through legitimate channels. Amycretin is a patented investigational drug that has never been commercially manufactured or approved. There is no FDA drug shortage listing. Any "compounded amycretin" or "zenagamtide" being sold online is an unregulated research chemical with unknown purity, potency, and safety. We strongly advise against purchasing it.

Frequently Asked Questions

Is amycretin FDA-approved? No. Amycretin entered Phase 3 trials in Q1 2026. FDA approval is not expected before 2029–2030.

How much does amycretin cost? Pricing has not been disclosed. Given Novo Nordisk's GLP-1 pricing history, expect a list price in the $1,000–$1,500/month range at launch if approved.

Who qualifies for amycretin? Currently only Phase 3 clinical trial participants. Search ClinicalTrials.gov for "amycretin" or "NNC0487-0111" for active trial sites.

What are the main side effects of amycretin? Nausea (~30%), vomiting, diarrhea — consistent with the GLP-1 class. No unexpected safety signals in Phase 1b/2 data.

How does amycretin compare to tirzepatide (Zepbound)? Amycretin showed 22% weight loss at 36 weeks vs. tirzepatide's 20.9% at 72 weeks — but tirzepatide is FDA-approved and available today. Amycretin is still in Phase 3.

When will amycretin be available? The earliest realistic window for the injectable is 2029–2030. The oral formulation is likely 2030 or later.

Is amycretin worth waiting for? For most patients, no. Effective GLP-1s are available now. Patients asking "is amycretin worth it" should discuss starting tirzepatide or semaglutide with their prescriber today.

This guide is for informational purposes only and does not constitute medical advice. Amycretin (zenagamtide) is an investigational medication that has not been approved by the FDA. All clinical data is based on published trial results and company disclosures, which are subject to change as additional data becomes available. Last updated April 2026.

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

Key Takeaways

Amycretin (Zenagamtide): Novo Nordisk's Next-Gen GLP-1/Amylin Agonist

What Is Amycretin?

How Does the GLP-1/Amylin Mechanism Work?

GLP-1 receptor: the established foundation

Amylin receptor: a different satiety pathway

Why the combination matters

How Effective Is Amycretin?

Phase 1b/2 Trial: Injectable Formulation

Phase 1b/2 Trial: Oral Formulation

What the early data tells us — and what it doesn't

Oral vs. Injectable: Two Paths Forward

The injectable path

The oral path

Why both matter

How Does Amycretin Compare to Existing and Pipeline GLP-1s?

Amycretin vs. Semaglutide (Wegovy)

Amycretin vs. Tirzepatide (Zepbound)

Amycretin vs. Retatrutide

Novo Nordisk's Strategy

The competitive context

Novo's pipeline positioning

The CagriSema connection

What this means for patients

When Will Amycretin Be Available?

What Are the Most Common Side Effects of Amycretin?

Gastrointestinal (most common)

The amylin factor

What we don't know yet

Frequently Asked Questions

Can I get amycretin now?

Is amycretin better than semaglutide?

How does amycretin compare to tirzepatide?

Will amycretin replace Wegovy?

What about the oral formulation — when will that be available?

How is amycretin different from CagriSema?

Should I wait for amycretin instead of starting a GLP-1 now?

Is the 22% weight loss number reliable?

What about compounded amycretin?

Frequently Asked Questions

More Guides

Does Aetna Cover GLP-1 Medications? 2026 Coverage Guide

Aleniglipron: Structure Therapeutics' Oral GLP-1 — What Patients Need to Know

AOD-9604 for Weight Loss: Telehealth Providers Guide 2026

Best GLP-1 Medication 2026: Every Approved Option Ranked by Use Case

Which GLP-1 Has the Fewest Side Effects? A Medication-by-Medication Comparison

Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026

Best GLP-1 Pill Options in 2026: Oral Wegovy, Orforglipron & More

Best Oral GLP-1 Options 2026: Foundayo vs Rybelsus Complete Comparison

Best GLP-1 Under $200 Per Month: 2026 Budget Guide

Best GLP-1 Weight Loss Programs 2026: Every Major Provider Ranked

Best Growth Hormone Peptide Providers Online: 2026 Independent Comparison

Best Online HRT 2026: Telehealth Menopause Treatment Platforms Compared

Best Online TRT Clinics 2026: Telehealth Testosterone Replacement Compared

Best Oral GLP-1 Options in 2026: Every Pill Compared

Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care

Best Weight Loss Injection 2026: Wegovy HD, Zepbound, and Every Option Compared

Best Weight Loss Medication 2026: Every FDA-Approved Option Ranked

Does Blue Cross Blue Shield Cover GLP-1 Medications? 2026 Guide

Best BPC-157 Telehealth Providers 2026: Complete Guide

BPC-157 vs TB-500: Which Injury Recovery Peptide Is Right for You?

CagriSema Dosing Guide: Titration Schedule, Dose Steps & What to Expect

CagriSema Launch Day Patient Guide: What to Do Now That It's Here

CagriSema: The Semaglutide + Cagrilintide Combination — Patient Guide

CagriSema FDA Decision Guide: What to Expect and How to Prepare

CagriSema: What Patients Need to Know While the FDA Decision Drags On

CagriSema Side Effects: What Clinical Trials Show About Safety and Tolerability

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

Cheapest GLP-1 Without Insurance in 2026: Every Option Ranked by Price

CJC-1295 vs Ipamorelin: Complete Telehealth Comparison Guide 2026

CMS BALANCE Model Explained: Medicaid Obesity Care for 2026 and Beyond

Medicare GLP-1 Bridge Program: Implementation FAQ for Patients

Compounded GLP-1 Shutdown Timeline: From Shortage to Enforcement (2023–2026)

Is Compounded HRT Safe? What Patients Need to Know in 2026

Is Compounded Semaglutide Legal and Safe in 2026?

Compounded Tirzepatide 2026: What's Happening and What Patients Should Do

Contrave Guide 2026: How It Works, Weight Loss Results & How It Compares to GLP-1s

Does Insurance Cover GLP-1 Medications? Complete 2026 Guide

Does Insurance Cover Semaglutide? 2026 Coverage Guide